From RTTNews:

Rigel Pharmaceuticals, Inc. expects to report net product sales of $104.3 million in 2023, a 36% growth over 2022. For the fourth quarter, the company expects total revenue of approximately $35.7 million. Additionally, Rigel expects to report cash, cash equivalents, and short-term investments of about $56.9 million as of December 31, 2023.

CEO Raul Rodriguez stated that the company experienced significant growth in its commercial hematology-oncology portfolio in 2023, with a nearly 24% increase in TAVALISSE net product sales compared to 2022. The company also achieved over $10 million of REZLIDHIA revenue in its first full year of launch, contributing to total net product sales of more than $104 million for the year.

For more health news, visit rttnews.com. For comments and feedback, contact [email protected]. Visit rttnews.com for more business news.



Read more: Rigel Pharmaceuticals Expects 2023 Net Product Sales To Rise 36%